However, R-2HG inhibits FTO in glioma, causing MYC/CEBPA mRNA methylation, disrupting the stability of these oncogene transcripts and inhibiting the activation of downstream oncogene pathways. The gene discussed is MYC; the disease is central nervous system cancer.